DeepX Health is pleased to announce that daughter-company ScreenCancer has been awarded support from Innovation Norway for its Diagnostic Triage Algorithm-project. The project’s ambition is to streamline ScreenCancer’s teledermatology service for skin cancer in pharmacies by triaging skin lesions using a skin cancer algorithm in order to reduce time spent by dermatologists upon analysis and to reduce human error. The algorithm to be used is a new specification of Balter Medical's DermoSight algorithm. This project therefore demonstrates the synergies within DeepX Health.
We are very grateful for the support given to us, and proud to share the acknowledgement of our work. We are excited to discover the effects of the project, and will provide an update once the results are clear!
DeepX Diagnostics Inc.'s DermoSight Receives FDA Clearance for Teledermatology Screening of Suspect Skin Cancer Lesions
Read morePharmacy Screening Demonstrates Great Efficiency and Potential for Cost Reductions
Read moreDeepX Health to Present at the 8th World Congress of Teledermatology, Imaging and Artificial Intelligence for Skin Diseases
Read moreDeepX Health to participate at the 7th Annual Dermatology Summit in San Francisco
Read more